Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage

British Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2009, Pages 462-463

  Alffenaar, Jan Willem C ^a   Van Der Elst, Kim C M ^a   Uges, Donald R A ^a   Kosterink, Jos G W ^a   Daenen, Simon M G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYTOCHROME P450 2C19; ETIRACETAM; PHENYTOIN; VORICONAZOLE;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; INFECTION RISK; LETTER; LUNG ASPERGILLOSIS; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; SEIZURE;

ANTICONVULSANTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PULMONARY ASPERGILLOSIS; PYRIMIDINES; TRIAZOLES;

EID: 69949152718     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03464.x     Document Type: Letter

References (10)

1. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 360.
2. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Co-administration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003 56 (Suppl. 1 37 44.
3. Pfizer. Vfend; product information. 19-3-2002.
4. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, Evens A, Mehta J. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007 109 : 1532 1535.
5. Alffenaar JW, de Vos T, Uges DR, Daenen SM. High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? Br J Clin Pharmacol 2009 67 : 262 263.
6. Gerzenshtein L, Patel SM, Scarsi KK, Postelnick MJ, Flaherty JP. Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother 2005 39 : 1342 1345.
7. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, Chen Y, Hu DL, Wang D, Zhou HH. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009 65 : 281 285.
8. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009 49 : 196 204.
9. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008 28 : 1502 1510.
10. Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008 30 : 1385 1407.